Neutrolis
Business Services · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1 Broadway Ste 14, Cambridge, Massachuse...Phone Number
(617) 863-3650Website
www.neutrolis.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Neutrolis
Neutrolis is a clinical stage company focused on developing first-in-class precision therapies for autoimmune and inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs). Their innovative exDNASE platform is designed to disassemble harmful NETs, addressing the root causes of immune-mediated disorders rather than just alleviating symptoms. Neutrolis aims to revolutionize treatment in this field and improve the lives of millions of patients globally. The company is committed to advancing translational medicine and enhancing the understanding of NETosis.Explore more
Neutrolis Org Chart
TF
Co-Founder, Co-President & CSO
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Neutrolis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Neutrolis
Check out if Neutrolis is spiking on competitors!
Neutrolis, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Neutrolis has recently received funding, and reach out quickly before it becomes old news!
Click to see if Neutrolis had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Neutrolis has new funding data
Earning: See what the market has to say on Neutrolis recently announced quarterly report
Product Launch: Get notified when Neutrolis launches new products
Recommended Actions
Find VP level buyers at Neutrolis
Find 3 more new buyers
Compare Similar Companies to Neutrolis
Compare insights from companies similar to Neutrolis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Neutrolis is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Neutrolis is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Neutrolis.
Neutrolis financials insights
Gather financial insights about Neutrolis, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Debt
$81K
Neutrolis Tech Stack
A closer look at the technologies used by Neutrolis
Most Recent Scoops
Person-Based
Proof of Concept (POC)
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Medical Research
New Hire
Executive Move
Executive Moves, New Hire
Project
Laboratory Operations, Medical Research, Clinical Operations
Neutrolis News & Media
Neutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer
CAMBRIDGE, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Neutrolis Inc. a clinical-stage biotechnology company focused on targeting Neutrophil Extracellular Traps (NETs) for the treatment of autoimmune and inflammatory diseases, today announced the appointment of Caren Deardorf as Chief Business & Strategy Officer (CBSO). Ms. Deardorf will lead corporate and pipeline strategy, business development, and early commercial strategy as the company advances its clinical pipeline.Neutrolis Announces Positive First-in-Human Phase 1a Results from LIBERATE-I Trial of NTR-1011, a First-in-Class DNASE1L3 Fusion Protein
CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Neutrolis, Inc., a clinical-stage biotechnology company pioneering a new class of rapid-acting, non-immunosuppressive therapies targeting Neutrophil Extracellular Traps (NETs), today announced positive topline results from the Phase 1a portion of its LIBERATE-I trial (NCT07237659) evaluating NTR-1011, a first-in-class DNASE1L3 fusion protein designed to dismantle pathogenic NETs and prevent their downstream proinflammatory effects that drive iNeutrolis Appoints Mikael Dolsten, M.D., Ph.D., to Board of Directors as Executive Director
CAMBRIDGE, Ma., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Neutrolis, a clinical-stage biotechnology company pioneering a new class of rapid-acting, non-immunosuppressive therapies that directly target Neutrophil Extracellular Traps (NETs) to revolutionize the treatment of inflammatory disorders, today announced the appointment of Mikael Dolsten, M.D., Ph.D., to its Board of Directors as Executive Director. Dr. Dolsten most recently served as Chief Scientific Officer and President of Worldwide Research,Neutrolis Presented First-in-Human Proof-of-Concept Data Validating DNASE1L3-Mediated Neutrophil Extracellular Trap (NET) Clearance as a Therapeutic Approach in Autoimmunity at American College of Rheumatology Convergence 2025
- First-in-human data validating direct targeting of NETs as a novel therapeutic approach in autoimmunity and inflammatory diseases
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Neutrolis
Sign Up For FreeTo access detailed company insights
Neutrolis is a clinical stage company focused on developing first-in-class precision therapies for autoimmune and inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs). Their innovative exDNASE platform is designed to disassemble harmful NETs, addressing the root causes of immune-mediated disorders rather than just alleviating sy... Read More
